|
|
Article: FDA announces that companies must stop marketing suppository products containing trimethobenzamide.
- Article from:
- M2 Presswire
- Article date:
- April 6, 2007
CopyrightCOPYRIGHT 2007 M2 Communications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-6 April 2007-US FDA: FDA announces that companies must stop marketing suppository products containing trimethobenzamide(C)1994-2007 M2 COMMUNICATIONS LTD
RDATE:06042007
As part of the Food and Drug Administration's (FDA) on-going initiative to ensure that all marketed U.S. drugs have required marketing approval, the agency announced today that companies must stop manufacturing and distributing unapproved suppository drug products containing trimethobenzamide hydrochloride. These products are used to treat nausea and vomiting in adults and children. Drugs containing trimethobenzamide in suppository form lack evidence of effectiveness. These ...